原发性胆汁性肝硬化自身抗体的研究进展  

Progress in the study of autoimmune antibodies in primary biliary cirrhosis

作　　者：龚晓蓉[1] 钟碧慧[1] 张盛洪[1] 陈旻湖[1] 

机构地区：[1]中山大学附属第一医院消化内科,广东广州510080

出　　处：《胃肠病学和肝病学杂志》2008年第12期1045-1048,共4页Chinese Journal of Gastroenterology and Hepatology

摘　　要：原发性胆汁性肝硬化(primary biliary cirrhosis,PBC)是一种原因不明的慢性胆汁淤积性自身免疫性肝病,其确切的发病机制尚未明确,可能涉及遗传、免疫及环境因素。其中体液免疫可能扮演了重要角色,引起了临床上的高度关注,血清中高滴度的抗线粒体抗体(antimitochondrial antibodies,AMA)已成为PBC诊断的重要指标。本文旨在探讨该领域的最新进展,以期加深对其发病机制的理解,为临床诊治提供进一步的依据。Primary biliary cirrhosis （PBC） is a chronic autoimmune cholestatic liver disease with unclear etiology, which may refer to genetics, immunology and environmental factors. More and more evidences suggest that humoral immunity plays an important role in the onset and development of PBC, which increasingly evokes the interest of many doctors. Antimitochondrial antibody （AMA） is an important diagnostic standard. The present article introduces the latest studies of PBC to further understand the etiology of PBC and provide new evidences for diagnosing and treating PBC.

关 键 词：原发性胆汁性肝硬化 自身免疫性 自身抗体 

分 类 号：R575.22[医药卫生—消化系统]